$12.15
2.36% yesterday
Nasdaq, Jun 12, 10:00 pm CET
ISIN
US5907171046
Symbol
MESO
Sector
Industry

Mesoblast Limited Sponsored ADR Stock price

$12.16
+0.81 7.14% 1M
+1.79 17.20% 6M
-7.64 38.59% YTD
+4.98 69.36% 1Y
-12.42 50.53% 5Y
-18.84 60.77% 10Y
+2.66 28.00% 20Y
Nasdaq, Closing price Thu, Jun 12 2025
+0.29 2.44%
ISIN
US5907171046
Symbol
MESO
Sector
Industry

Key metrics

Market capitalization $1.50b
Enterprise Value $1.59b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 280.37
P/S ratio (TTM) P/S ratio 264.77
P/B ratio (TTM) P/B ratio 30.38
Revenue growth (TTM) Revenue growth -24.10%
Revenue (TTM) Revenue $5.67m
EBIT (operating result TTM) EBIT $-80.20m
Free Cash Flow (TTM) Free Cash Flow $-42.72m
Cash position $37.66m
EPS (TTM) EPS $-0.09
P/E forward negative
P/S forward 77.38
EV/Sales forward 81.94
Short interest 2.60%
Show more

Is Mesoblast Limited Sponsored ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,845 stocks worldwide.

Mesoblast Limited Sponsored ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

4 Analysts have issued a Mesoblast Limited Sponsored ADR forecast:

4x Buy
100%

Analyst Opinions

4 Analysts have issued a Mesoblast Limited Sponsored ADR forecast:

Buy
100%

Financial data from Mesoblast Limited Sponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
5.67 5.67
24% 24%
100%
- Direct Costs -5.77 -5.77
127% 127%
-102%
11 11
180% 180%
202%
- Selling and Administrative Expenses 29 29
24% 24%
517%
- Research and Development Expense 33 33
30% 30%
588%
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -80 -80
45% 45%
-1,414%
Net Profit -103 -103
41% 41%
-1,823%

In millions USD.

Don't miss a Thing! We will send you all news about Mesoblast Limited Sponsored ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Mesoblast Limited Sponsored ADR Stock News

Neutral
GlobeNewsWire
one day ago
NEW YORK, June 11, 2025 (GLOBE NEWSWIRE) -- Mesoblast (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an update on continued momentum with United States Food and Drug Administration (FDA) regarding both accelerated approval pathway for Revascor® (rexlemestrocel-L) in the treatment of patients with ischemic chronic heart failure wi...
Neutral
GlobeNewsWire
29 days ago
NEW YORK, May 14, 2025 (GLOBE NEWSWIRE) -- Mesoblast (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has received seven years of orphan-drug exclusive approval from U.S. Food and Drug Administration (FDA) for Ryoncil® (remestemcel-L) for treatment of steroid-refractory acute graft versus host disease (SR-aGvHD) in pediatr...
Positive
Seeking Alpha
about one month ago
MESO's Off-the-shelf MSC/MPC platform treats severe inflammatory diseases without donor–recipient matching. This alleviates the typical need for immunosuppression. The FDA recently approved Ryoncil, which achieved as much as 70% response in pediatric SR-aGVHD patients. And it has adult SR-aGVHD and Crohn's Phase 3 trials underway. MESO's Revascor is also in trials for chronic low back pain and ...
More Mesoblast Limited Sponsored ADR News

Company Profile

Mesoblast Ltd. is a biopharmaceutical company, which engages in the research, development, and market of mesenchymal lineage adult stem cell technology platform. Its medicines target the cardiovascular diseases, spine orthopedic disorders, oncology and hematology, immune-mediated, and inflammatory diseases. The company was founded by Itescu Silviu on June 8, 2004 and is headquartered in Melbourne, Australia.

Head office Australia
CEO Silviu Itescu
Employees 73
Founded 2004
Website www.mesoblast.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today